title: Anti-inflammatory, Antithrombotic and Cardiac Remodeling Preventive Effects of Eugenol in Isoproterenol-Induced Myocardial Infarction in Wistar Rat.
abstract: This study aimed to evaluate the antithrombotic, anti-inflammatory and anti-cardiac remodeling properties of eugenol in isoproterenol-induced myocardial infarction in rats. Male Wistar rats were randomly divided into four groups, control, iso [100 mg/kg body weight was injected subcutaneously into rats at an interval of 24 h for 2 days (6th and 7th day) to induce MI] and pretreated animals with clopidogrel (0.2 mg/kg) and eugenol (50 mg/kg) orally for 7 days and intoxicated with isoproterenol (Iso + Clop) and (Iso + EG) groups. Isoproterenol-induced myocardial infarcted rats showed notable changes in the ECG pattern, increase in heart weight index, deterioration in the hemodynamic function and rise in plasma level of troponin-T, CK-MB and LDH and ALT by 316, 74, 172 and 45 %, respectively, with histological myocardium necrosis and cells inflammatory infiltration. In addition, significant increases in plasma levels of inflammatory biomarkers such as fibrinogen, α1, α2, β1, β2 and γ globulins with decrease level of albumin were observed in infarcted rats as compared to normal ones. Else, the angiotensin-converting enzyme (ACE) activity in plasma, kidney and heart of the isoproterenol-induced rats was significantly increased by 34, 47 and 93 %, respectively, as compared to normal group. However, the administration of eugenol induced a clear improvement in cardiac biomarkers injury, reduced inflammatory mediators proteins, increased heart activities of superoxide dismutase and glutathione peroxidase with reduce in thiobarbituric acid-reactive substances content and inhibition of ventricular remodeling process through inhibition of ACE activity. Overall, eugenol evidences high preventive effects from cardiac remodeling process.
authors.affiliation: Laboratory of Animal Physiology, Faculty of Sciences of Sfax, University of Sfax, P.O. Box 95, 3052, Sfax, Tunisia. mnafgui_kais@yahoo.fr.|Department of Internal medicine, Hospital of Sidi Bouzid, 9100, Sidi Bouzid, Tunisia. mnafgui_kais@yahoo.fr.
authors.forename: Kais
authors.initials: K
authors.lastname: Mnafgui
authors.affiliation: Department of Internal medicine, Hospital of Sidi Bouzid, 9100, Sidi Bouzid, Tunisia.
authors.forename: Raouf
authors.initials: R
authors.lastname: Hajji
authors.affiliation: Department of Internal medicine, Hospital of Sidi Bouzid, 9100, Sidi Bouzid, Tunisia.
authors.forename: Fatma
authors.initials: F
authors.lastname: Derbali
authors.affiliation: Department of Urology, Hospital of Sidi Bouzid, 9100, Sidi Bouzid, Tunisia.
authors.forename: Anis
authors.initials: A
authors.lastname: Gammoudi
authors.affiliation: Department of Nephrology, Hospital of Sidi Bouzid, 9100, Sidi Bouzid, Tunisia.
authors.forename: Gaddour
authors.initials: G
authors.lastname: Khabbabi
authors.affiliation: Department of Cardiology, Centre Hospitalier Intercommunal Robert Ballanger, Boulevard Robert Ballanger, 93600, Aulnay-Sous-Bois, France.
authors.forename: Hedi
authors.initials: H
authors.lastname: Ellefi
authors.affiliation: Laboratory of Chemistry of Natural Products, Faculty of Sciences of Sfax, B.P. 1171, 3000, Sfax, Tunisia.
authors.forename: Noureddine
authors.initials: N
authors.lastname: Allouche
authors.affiliation: Laboratory of Plant Biotechnology, Faculty of Sciences of Sfax, B.P. 1171, 3000, Sfax, Tunisia.
authors.forename: Adel
authors.initials: A
authors.lastname: Kadri
authors.affiliation: Laboratory of Plant Biotechnology, Faculty of Sciences of Sfax, B.P. 1171, 3000, Sfax, Tunisia.
authors.forename: Neji
authors.initials: N
authors.lastname: Gharsallah
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects*; D016207:Cytokines / Q000097:blood*; D004195:Disease Models, Animal; D005054:Eugenol / Q000494:pharmacology*; D005340:Fibrinogen / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006439:Hemodynamics / Q000187:drug effects; D018836:Inflammation Mediators / Q000097:blood*; D007545:Isoproterenol; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D009203:Myocardial Infarction / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D009336:Necrosis; D018384:Oxidative Stress / Q000187:drug effects; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism; D017208:Rats, Wistar; D012084:Renin-Angiotensin System / Q000187:drug effects; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D015415:Biomarkers; D016207:Cytokines; D005343:Fibrinolytic Agents; D018836:Inflammation Mediators; D005054:Eugenol; D005340:Fibrinogen; D007703:Peptidyl-Dipeptidase A; D007545:Isoproterenol
keywords: ACE; Eugenol; Fibrinogen; Inflammation; Myocardial infarction